IBDEI0PU ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,11616,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,11616,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,11617,0)
;;=I13.2^^46^563^7
;;^UTILITY(U,$J,358.3,11617,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11617,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
;;^UTILITY(U,$J,358.3,11617,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,11617,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,11618,0)
;;=I70.1^^46^563^3
;;^UTILITY(U,$J,358.3,11618,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11618,1,3,0)
;;=3^Atherosclerosis of Renal Artery
;;^UTILITY(U,$J,358.3,11618,1,4,0)
;;=4^I70.1
;;^UTILITY(U,$J,358.3,11618,2)
;;=^269760
;;^UTILITY(U,$J,358.3,11619,0)
;;=I77.3^^46^563^2
;;^UTILITY(U,$J,358.3,11619,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11619,1,3,0)
;;=3^Arterial Fibromuscular Dysplasia
;;^UTILITY(U,$J,358.3,11619,1,4,0)
;;=4^I77.3
;;^UTILITY(U,$J,358.3,11619,2)
;;=^5007812
;;^UTILITY(U,$J,358.3,11620,0)
;;=E26.02^^46^563^5
;;^UTILITY(U,$J,358.3,11620,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11620,1,3,0)
;;=3^Glucocorticoid-Remediable Aldosteronism
;;^UTILITY(U,$J,358.3,11620,1,4,0)
;;=4^E26.02
;;^UTILITY(U,$J,358.3,11620,2)
;;=^329904
;;^UTILITY(U,$J,358.3,11621,0)
;;=I12.9^^46^563^14
;;^UTILITY(U,$J,358.3,11621,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11621,1,3,0)
;;=3^Hypertensive CKD Stage 1-4
;;^UTILITY(U,$J,358.3,11621,1,4,0)
;;=4^I12.9
;;^UTILITY(U,$J,358.3,11621,2)
;;=^5007066
;;^UTILITY(U,$J,358.3,11622,0)
;;=I12.0^^46^563^15
;;^UTILITY(U,$J,358.3,11622,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11622,1,3,0)
;;=3^Hypertensive CKD Stage 5 or ESRD
;;^UTILITY(U,$J,358.3,11622,1,4,0)
;;=4^I12.0
;;^UTILITY(U,$J,358.3,11622,2)
;;=^5007065
;;^UTILITY(U,$J,358.3,11623,0)
;;=I13.0^^46^563^6
;;^UTILITY(U,$J,358.3,11623,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11623,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
;;^UTILITY(U,$J,358.3,11623,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,11623,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,11624,0)
;;=I13.10^^46^563^9
;;^UTILITY(U,$J,358.3,11624,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11624,1,3,0)
;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
;;^UTILITY(U,$J,358.3,11624,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,11624,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,11625,0)
;;=I15.1^^46^563^11
;;^UTILITY(U,$J,358.3,11625,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11625,1,3,0)
;;=3^Hypertension Secondary to Oth Renal Disorders
;;^UTILITY(U,$J,358.3,11625,1,4,0)
;;=4^I15.1
;;^UTILITY(U,$J,358.3,11625,2)
;;=^5007072
;;^UTILITY(U,$J,358.3,11626,0)
;;=I15.2^^46^563^10
;;^UTILITY(U,$J,358.3,11626,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11626,1,3,0)
;;=3^Hypertension Secondary to Endocrine Disorders
;;^UTILITY(U,$J,358.3,11626,1,4,0)
;;=4^I15.2
;;^UTILITY(U,$J,358.3,11626,2)
;;=^5007073
;;^UTILITY(U,$J,358.3,11627,0)
;;=I50.1^^46^563^16
;;^UTILITY(U,$J,358.3,11627,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11627,1,3,0)
;;=3^Left Ventricular Failure
;;^UTILITY(U,$J,358.3,11627,1,4,0)
;;=4^I50.1
;;^UTILITY(U,$J,358.3,11627,2)
;;=^5007238
;;^UTILITY(U,$J,358.3,11628,0)
;;=E26.09^^46^563^17
;;^UTILITY(U,$J,358.3,11628,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11628,1,3,0)
;;=3^Primary Hyperaldosteronism,Other
;;^UTILITY(U,$J,358.3,11628,1,4,0)
;;=4^E26.09
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0PU 3783 printed Sep 15, 2024@21:17:40 Page 2
IBDEI0PU ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,11616,1,4,0)
+2 ;;=4^I13.11
+3 ;;^UTILITY(U,$J,358.3,11616,2)
+4 ;;=^5007069
+5 ;;^UTILITY(U,$J,358.3,11617,0)
+6 ;;=I13.2^^46^563^7
+7 ;;^UTILITY(U,$J,358.3,11617,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,11617,1,3,0)
+10 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
+11 ;;^UTILITY(U,$J,358.3,11617,1,4,0)
+12 ;;=4^I13.2
+13 ;;^UTILITY(U,$J,358.3,11617,2)
+14 ;;=^5007070
+15 ;;^UTILITY(U,$J,358.3,11618,0)
+16 ;;=I70.1^^46^563^3
+17 ;;^UTILITY(U,$J,358.3,11618,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,11618,1,3,0)
+20 ;;=3^Atherosclerosis of Renal Artery
+21 ;;^UTILITY(U,$J,358.3,11618,1,4,0)
+22 ;;=4^I70.1
+23 ;;^UTILITY(U,$J,358.3,11618,2)
+24 ;;=^269760
+25 ;;^UTILITY(U,$J,358.3,11619,0)
+26 ;;=I77.3^^46^563^2
+27 ;;^UTILITY(U,$J,358.3,11619,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,11619,1,3,0)
+30 ;;=3^Arterial Fibromuscular Dysplasia
+31 ;;^UTILITY(U,$J,358.3,11619,1,4,0)
+32 ;;=4^I77.3
+33 ;;^UTILITY(U,$J,358.3,11619,2)
+34 ;;=^5007812
+35 ;;^UTILITY(U,$J,358.3,11620,0)
+36 ;;=E26.02^^46^563^5
+37 ;;^UTILITY(U,$J,358.3,11620,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,11620,1,3,0)
+40 ;;=3^Glucocorticoid-Remediable Aldosteronism
+41 ;;^UTILITY(U,$J,358.3,11620,1,4,0)
+42 ;;=4^E26.02
+43 ;;^UTILITY(U,$J,358.3,11620,2)
+44 ;;=^329904
+45 ;;^UTILITY(U,$J,358.3,11621,0)
+46 ;;=I12.9^^46^563^14
+47 ;;^UTILITY(U,$J,358.3,11621,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,11621,1,3,0)
+50 ;;=3^Hypertensive CKD Stage 1-4
+51 ;;^UTILITY(U,$J,358.3,11621,1,4,0)
+52 ;;=4^I12.9
+53 ;;^UTILITY(U,$J,358.3,11621,2)
+54 ;;=^5007066
+55 ;;^UTILITY(U,$J,358.3,11622,0)
+56 ;;=I12.0^^46^563^15
+57 ;;^UTILITY(U,$J,358.3,11622,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,11622,1,3,0)
+60 ;;=3^Hypertensive CKD Stage 5 or ESRD
+61 ;;^UTILITY(U,$J,358.3,11622,1,4,0)
+62 ;;=4^I12.0
+63 ;;^UTILITY(U,$J,358.3,11622,2)
+64 ;;=^5007065
+65 ;;^UTILITY(U,$J,358.3,11623,0)
+66 ;;=I13.0^^46^563^6
+67 ;;^UTILITY(U,$J,358.3,11623,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,11623,1,3,0)
+70 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
+71 ;;^UTILITY(U,$J,358.3,11623,1,4,0)
+72 ;;=4^I13.0
+73 ;;^UTILITY(U,$J,358.3,11623,2)
+74 ;;=^5007067
+75 ;;^UTILITY(U,$J,358.3,11624,0)
+76 ;;=I13.10^^46^563^9
+77 ;;^UTILITY(U,$J,358.3,11624,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,11624,1,3,0)
+80 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
+81 ;;^UTILITY(U,$J,358.3,11624,1,4,0)
+82 ;;=4^I13.10
+83 ;;^UTILITY(U,$J,358.3,11624,2)
+84 ;;=^5007068
+85 ;;^UTILITY(U,$J,358.3,11625,0)
+86 ;;=I15.1^^46^563^11
+87 ;;^UTILITY(U,$J,358.3,11625,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,11625,1,3,0)
+90 ;;=3^Hypertension Secondary to Oth Renal Disorders
+91 ;;^UTILITY(U,$J,358.3,11625,1,4,0)
+92 ;;=4^I15.1
+93 ;;^UTILITY(U,$J,358.3,11625,2)
+94 ;;=^5007072
+95 ;;^UTILITY(U,$J,358.3,11626,0)
+96 ;;=I15.2^^46^563^10
+97 ;;^UTILITY(U,$J,358.3,11626,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,11626,1,3,0)
+100 ;;=3^Hypertension Secondary to Endocrine Disorders
+101 ;;^UTILITY(U,$J,358.3,11626,1,4,0)
+102 ;;=4^I15.2
+103 ;;^UTILITY(U,$J,358.3,11626,2)
+104 ;;=^5007073
+105 ;;^UTILITY(U,$J,358.3,11627,0)
+106 ;;=I50.1^^46^563^16
+107 ;;^UTILITY(U,$J,358.3,11627,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,11627,1,3,0)
+110 ;;=3^Left Ventricular Failure
+111 ;;^UTILITY(U,$J,358.3,11627,1,4,0)
+112 ;;=4^I50.1
+113 ;;^UTILITY(U,$J,358.3,11627,2)
+114 ;;=^5007238
+115 ;;^UTILITY(U,$J,358.3,11628,0)
+116 ;;=E26.09^^46^563^17
+117 ;;^UTILITY(U,$J,358.3,11628,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,11628,1,3,0)
+120 ;;=3^Primary Hyperaldosteronism,Other
+121 ;;^UTILITY(U,$J,358.3,11628,1,4,0)
+122 ;;=4^E26.09
